Effects of acute administration of melatonin on attentional, executive, and working memory processes in rats

Fundamental and Clinical Pharmacology

Volumn 29, Issue 5, 2015, Pages 472-477

  Liet, Christophe ^a,b,c   Amenouche, Fella ^a,b,c   Freret, Thomas ^a,d   Boulouard, Michel ^a,d   Mauvieux, Benoit ^a,b,c   Lelong Boulouard, Véronique ^a,b,c,e   Bocca, Marie Laure ^a,b,c  

^a NORMANDIE UNIVERSITÉ   (France)

^b INSERM U1075   (France)

^c INSERM   (France)

^d UCBN   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Activity phase; Attentional Set Shifting; Cognitive effect; Melatonin; Rodent

Indexed keywords

MELATONIN;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ARTICLE; ATTENTION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; EXECUTIVE FUNCTION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; WORKING MEMORY; Y-MAZE TEST; ANIMAL; ANIMAL BEHAVIOR; COGNITION; DRUG EFFECTS; MOTOR ACTIVITY; SHORT TERM MEMORY; SPRAGUE DAWLEY RAT; TIME FACTOR;

ANIMALS; ATTENTION; BEHAVIOR, ANIMAL; COGNITION; EXECUTIVE FUNCTION; MALE; MELATONIN; MEMORY, SHORT-TERM; MOTOR ACTIVITY; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84941736863     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12134     Document Type: Article

References (31)

1. Pévet P. Melatonin in animal models. Dialogues Clin. Neurosci. (2003) 5 343.
2. Claustrat B., Brun J., Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med. Rev. (2005) 9 11-24.
3. Kostoglou-Athanassiou I. Therapeutic applications of melatonin. Ther. Adv. Endocrinol. Metab. (2013) 4 13-24.
4. Vermeeren A., Coenen A.M.L. Effects of the use of hypnotics on cognition. Prog. Brain Res. Elsevier (2011) 190 89-103.
5. Macchi M.M., Bruce J.N. Human pineal physiology and functional significance of melatonin. Front. Neuroendocrinol. (2004) 25 177-195.
6. Sharma A.K., Mehta A.K., Rathor N., Chalawadi Hanumantappa M.K., Khanna N., Bhattacharya S.K. Melatonin attenuates cognitive dysfunction and reduces neural oxidative stress induced by phosphamidon. Fundam. Clin. Pharmacol. (2013) 27 146-151.
7. Furio A.M., Brusco L.I., Cardinali D.P. Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J. Pineal Res. (2007) 43 404-409.
8. Srinivasan V., Pandi-Perumal S.R., Brzezinski A., Bhatnagar K.P., Cardinali D.P. Melatonin, immune function and cancer. Recent Pat. Endocr. Metab. Immune Drug Discov. (2011) 5 109-123.
9. Suhner A., Schlagenhauf P., Tschopp A., Hauri-Bionda R., Friedrich-Koch A., Steffen R. Impact of melatonin on driving performance. J. Travel Med. (1998) 5 7-13.
10. Tasdemir S., Parlakpinar H., Vardi N., Kaya E., Acet A. Effect of endogen-exogenous melatonin and erythropoietin on dinitrobenzene sulfonic acid-induced colitis: effect of melatonin and EPO on colitis. Fundam. Clin. Pharmacol. (2013) 27 299-307.
11. Graw P., Werth E., Kräuchi K., Gutzwiller F., Cajochen C., Wirz-Justice A. Early morning melatonin administration impairs psychomotor vigilance. Behav. Brain Res. (2001) 121 167-172.
12. Weaver D.R., Rivkees S.A., Reppert S.M. Localization and characterization of melatonin receptors in rodent brain by in vitro autoradiography. J. Neurosci. (1989) 9 2581-2590.
13. Pandiperumal S., Trakht I., Srinivasan V. et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog. Neurobiol. (2008) 85 335-353.
14. Rawashdeh O., de Borsetti N.H., Roman G., Cahill G.M. Melatonin suppresses nighttime memory formation in zebrafish. Science (2007) 318 1144-1146.
15. Cao X.J., Wang M., Chen W.H., Zhu D.M., She J.Q., Ruan D.Y. Effects of chronic administration of melatonin on spatial learning ability and long-term potentiation in lead-exposed and control rats. Biomed. Environ. Sci. (2009) 22 70-75.
16. Chattoraj A., Liu T., Zhang L.S., Huang Z., Borjigin J. Melatonin formation in mammals: in vivo perspectives. Rev. Endocr. Metab. Disord. (2009) 10 237-243.
17. Ochoa-Sanchez R., Rainer Q., Comai S. et al. Anxiolytic effects of the melatonin MT2 receptor partial agonist UCM765: comparison with melatonin and diazepam. Prog. Neuropsychopharmacol. Biol. Psychiatry (2012) 39 318-325.
18. Ochoa-Sanchez R., Comai S., Spadoni G., Bedini A., Tarzia G., Gobbi G. Melatonin, selective and non-selective MT1/MT2 receptors agonists: differential effects on the 24-h vigilance states. Neurosci. Lett. (2014) 561 156-161.
19. Birrell J.M., Brown V.J. Medial frontal cortex mediates perceptual attentional set shifting in the rat. J. Neurosci. (2000) 20 4320-4324.
20. Sarter M., Bodewitz G., Stephens D.N. Attenuation of scopolamine-induced impairment of spontaneous alternation behaviour by antagonist but not inverse agonist and agonist β-carbolines. Psychopharmacology (1988) 94 491-495.
21. Warren W.S., Hodges D.B., Cassone V.M. Pinealectomized rats entrain and phase-shift to melatonin injections in a dose-dependent manner. J. Biol. Rhythms (1993) 8 233-245.
22. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. (2007) 22 659-661.
23. Cardinali D.P., Vigo D.E., Olivar N., Vidal M.F., Furio A.M., Brusco L.I. Therapeutic application of melatonin in mild cognitive impairment. Am. J. Neurodegener. Dis. (2012) 1 280.
24. Weishaupt J.H., Bartels C., Pölking E. et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J. Pineal Res. (2006) 41 313-323.
25. Lissoni P. Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent. Pathol. Biol. (2007) 55 198-200.
26. Joly F., Rigal O., Noal S., Giffard B. Cognitive dysfunction and cancer: which consequences in terms of disease management? Psychooncology (2011) 20 1251-1258.
27. Zhdanova I.V., Yu L., Lopez-Patino M., Shang E., Kishi S., Guelin E. Aging of the circadian system in zebrafish and the effects of melatonin on sleep and cognitive performance. Brain Res. Bull. (2008) 75 433-441.
28. Otmani S., Demazières A., Staner C. et al. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum. Psychopharmacol (2008) 23 693-705.
29. Rawashdeh O., Maronde E. The hormonal Zeitgeber melatonin: role as a circadian modulator in memory processing. Front. Mol. Neurosci. (2012) 5 1-6.
30. Sotomoyano R., Burgos H., Flores F. et al. Melatonin administration impairs visuo-spatial performance and inhibits neocortical long-term potentiation in rats. Pharmacol. Biochem. Behav. (2006) 85 408-414.
31. Bertaina-Anglade V., Drieu-La-Rochelle C., Mocaër E., Seguin L. Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat. Pharmacol. Biochem. Behav. (2011) 98 511-517.